Form 4 for CORT CORCEPT THERAPEUTICS INC
Accepted 2025-06-04 00:00:00 ET · period of report 2025-06-02 · accession 0000950170-25-081935 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2025-06-04 | 2025-06-02 | CORT | Lyon Joseph Douglas | See Remarks | A - Grant | $35.84 | +1,498 | 9,758 | +18% | +$53.7K |
| DMT | 2025-06-04 | 2025-06-02 | CORT | Lyon Joseph Douglas | See Remarks | S - Sale+OE | $78.05 | -5,000 | 9,751 | -34% | -$390.2K |
| DT | 2025-06-04 | 2025-06-02 | CORT | Lyon Joseph Douglas | See Remarks | M - OptEx | $13.56 | +5,000 | 14.0K | +56% | +$67.8K |
| DT | 2025-06-04 | 2025-06-03 | CORT | Lyon Joseph Douglas | See Remarks | F - Tax | $71.68 | -441 | 10.1K | -4% | -$31.6K |
| DT | 2025-06-04 | 2025-06-02 | CORT | Lyon Joseph Douglas | See Remarks | M - OptEx | $0.00 | -5,000 | 41.6K | -11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-02 | A | A | 749 | $0.00 | 10,507 | D | — | — | (F7) Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary. (F1) Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 2 | Common | Common Stock | 2025-06-02 | A | A | 749 | $71.68 | 9,758 | D | — | — | (F5) The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025. (F6) In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase. (F1) Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 3 | Common | Common Stock | 2025-06-02 | S | D | 562 | $78.65 | 9,009 | D | — | — | (F4) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $78.74 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. (F1) Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 4 | Common | Common Stock | 2025-06-02 | S | D | 4,438 | $77.97 | 9,751 | D | — | — | (F3) Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.55 per share. Information on the exact number of shares sold at each sale price can be obtained from the issuer upon request. (F1) Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 5 | Common | Common Stock | 2025-06-02 | M | A | 5,000 | $13.56 | 14,009 | D | — | — | (F1) Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 6 | Common | Common Stock | 2025-06-03 | F | D | 441 | $71.68 | 10,066 | D | — | — | (F9) The closing price on June 2, 2025 was used to calculate the withholding obligation. (F1) Includes 372 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 215 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 216 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements. |
| 7 | Derivative | Stock option (right to buy) | 2025-06-02 | M | D | 5,000 | $0.00 | 41,571 | D | $13.56 · — to 2030-02-07 | 5,000 Common Stock | (F10) Fully exercisable. |